NIH R01 · 2025
Project Summary/Abstract Triple negative breast cancer (TNBC) is aggressive and a large percentage of patients develop metastatic disease. Disseminated tumor cells (DTCs) found in the bone marrow (BM) of TNBC patients may be the intermediaries of the metastatic process. Data from our lab as well as others suggest that the immune landscape of BM may influence DTC latency, treatment resistance, and metastatic potential. We have already defined and validated an 8 gene expression-based biomarker panel that can detect DTCs in the BM of treatment naïve TNBC patients and that predicts development of distant metastatic disease. Our recent data indicate that TNBC patients with DTC-positive BM have…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.